Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas
about
Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cellsSyndecans in tumor cell adhesion and signalingClonogenic growth of human breast cancer cells co-cultured in direct contact with serum-activated fibroblasts.Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and PrognosticationSelectivity in glycosaminoglycan binding dictates the distribution and diffusion of fibroblast growth factors in the pericellular matrix.FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancerInsights into the key roles of proteoglycans in breast cancer biology and translational medicineA joint analysis of transcriptomic and metabolomic data uncovers enhanced enzyme-metabolite coupling in breast cancer.Gene set internal coherence in the context of functional profiling.Effect of syndecan-1 overexpression on mesenchymal tumour cell proliferation with focus on different functional domains.Heparanase and hepatocellular carcinoma: promoter or inhibitor?The motile breast cancer phenotype roles of proteoglycans/glycosaminoglycans.Heparan sulfate proteoglycans and human breast cancer epithelial cell tumorigenicity.Syndecan-1 and syndecan-4 are independent indicators in breast carcinomaAgrin and perlecan mediate tumorigenic processes in oral squamous cell carcinoma.Acquisition of anoikis resistance up-regulates syndecan-4 expression in endothelial cells.Structural and functional changes in heparan sulfate proteoglycan expression associated with the myofibroblastic phenotypeBreast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans.The role of the extracellular matrix in angiogenesis in malignant glioma tumors.Proteoglycans in cancer biology, tumour microenvironment and angiogenesis.Heparan sulfate and heparanase as modulators of breast cancer progressionProteoglycans: master modulators of paracrine fibroblast-carcinoma cell interactions.Structure and function of the skeletal muscle extracellular matrix.Glycosaminoglycans: key players in cancer cell biology and treatment.Syndecans as modulators and potential pharmacological targets in cancer progression.Roles of glycosaminoglycans and glycanmimetics in tumor progression and metastasis.Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression.Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation.In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas. Loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation.Syndecan-1 regulates FGF8b responses in S115 mammary carcinoma cells.Physiology and gene expression characteristics of carcinogen-initiated and tumor-transformed glial progenitor cells derived from the CNS of methylnitrosourea (MNU)-treated Sprague-Dawley rats.Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B.Expression of syndecan-4 and correlation with metastatic potential in testicular germ cell tumours.Prostaglandin F2alpha involves heparan sulphate sugar chains and FGFRs to modulate osteoblast growth and differentiation.Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis.Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer.Association of heparan sulfate proteoglycans SDC1 and SDC4 polymorphisms with breast cancer in an Australian Caucasian population.Dually modified transmembrane proteoglycans in development and disease.The GAG-specific branched peptide NT4 reduces angiogenesis and invasiveness of tumor cells.
P2860
Q24674858-91E20D43-8483-4618-BFC4-4C56A454301DQ24807364-A3233A36-7ED9-455A-A02F-7172D53716EAQ24810282-32908EA3-44F9-4083-A623-7B60968D06A5Q26784262-D77FA94F-3A24-4FD6-89ED-250C52442ED5Q27336444-7B7B51C7-5854-478B-B99B-33410A34656EQ27851554-05740507-8E1B-48F9-BF80-F9042613F155Q28085548-185F8B17-BB8A-46CC-96BC-4A7034806568Q31114185-1C602A57-B399-46F5-AC70-EE396754BA8CQ33435680-E86F80CF-40E5-4E2B-93B6-D1F39D9F6FF7Q33511333-60B6278D-9EB1-4D04-A5D4-BDD37D6C7956Q33596487-737761C0-8DF4-4B7F-B258-3E8F4DB54BE6Q34031745-A3C7782D-7778-4484-B267-BE0D1330A633Q34475894-277AC5DD-74B3-4D91-B38C-78ABCC498CE6Q35441324-7897DECA-4FA3-480A-8E24-5856CFB053A7Q35519929-53114D33-687F-49B7-9CA9-36FCEC2BF2A2Q35535743-B9AC45A5-563B-4E17-A29A-7CFFDA3DBA81Q35754809-24C813C1-C875-42BE-9477-9653DB02EDE7Q35768137-4DC75AA5-FE1E-4AB9-9786-6E371EB2A515Q36359232-B8E584FC-E725-4A0B-AB7E-6E5ACCB5EBD3Q36787608-6D5D4E32-BB95-4A3D-9DCF-A029481FC0D0Q37105315-1753D46E-2C59-4C44-BBE6-0E1959AF7196Q37636855-3D74F5C4-02DF-433E-BA29-3D6895D37B78Q37939096-59FCA8B2-8662-42D1-BB4C-F096EB0BB892Q37983930-52423175-EB02-4F1B-A33D-1530B64A8DF9Q38189392-D37C1EA0-3C19-4AAF-B986-34F0617644AFQ38250158-67028264-4F53-48B5-91D1-D3BF6DA5BBF7Q38357653-CE328114-66B4-4553-9166-BB5CB3D47D35Q40162051-AA9331FC-373B-454C-A1BD-F6CD9338536BQ40205392-0AC54D5A-40EC-424F-99E6-3287ED31C908Q40262635-FA092B98-5137-49DB-B7AB-0541829D6CC0Q40484443-6F56BB5F-2A53-4A9C-98D4-E22323BB1948Q41437410-F8A1F824-9DD6-4050-992A-6EE51AB794E7Q41444734-64123A4C-1434-4EDA-A15C-2D2B0AE89CE7Q42435671-D9EC8325-B985-44F8-9C30-5B01035FCCFEQ42808742-44D3A4FE-116B-4E80-BE57-F71D571FBE33Q43263196-7230B9A4-CAAE-445D-B3AF-140CCAC07BD9Q43752663-604BEC33-42E2-44E3-BAC2-0E2784FE3A39Q47240245-F1BD7FD7-1AD2-4534-996C-91B2DC4985BCQ55318767-71669C64-C5ED-46C5-BB55-B89E0BD0C94B
P2860
Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Heparan sulfate proteoglycans ...... r binding in breast carcinomas
@ast
Heparan sulfate proteoglycans ...... r binding in breast carcinomas
@en
Heparan sulfate proteoglycans ...... r binding in breast carcinomas
@nl
type
label
Heparan sulfate proteoglycans ...... r binding in breast carcinomas
@ast
Heparan sulfate proteoglycans ...... r binding in breast carcinomas
@en
Heparan sulfate proteoglycans ...... r binding in breast carcinomas
@nl
prefLabel
Heparan sulfate proteoglycans ...... r binding in breast carcinomas
@ast
Heparan sulfate proteoglycans ...... r binding in breast carcinomas
@en
Heparan sulfate proteoglycans ...... r binding in breast carcinomas
@nl
P2093
P2860
P3181
P1476
Heparan sulfate proteoglycans ...... r binding in breast carcinomas
@en
P2093
Andreas Friedl
Christoph Mundhenke
Kristy Meyer
Sally Drew
P2860
P304
P3181
P356
10.1016/S0002-9440(10)64362-3
P407
P577
2002-01-01T00:00:00Z